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Abstract  
Purpose. Our aim was to use quantitative and qualitative analyses to gain further insight into the role of ceramide in 
Cystic Fibrosis (CF). Sphingolipid ceramide is a known inflammatory mediator and its accumulation in inflamed lung 
has been reported in different types of emphysema, Chronic Obstructive Pulmonary disease and CF. CF is caused by a 
mutation of the chloride channel and associated with hyper-inflammation of the respiratory airways and high susceptibility 
to on-going infections. We have previously demonstrated that de novo ceramide synthesis is enhanced in lung 
inflammation and sustains P. aeruginosa pulmonary infection in a CF murine model. Methods. We used Liquid 
Chromatography and MALDI Imaging coupled with Mass Spectrometry, Confocal Laser Scan Microscopy and histology 
analyses to reveal otherwise undecipherable information. Results. We demonstrated that i) up-regulated ceramide 
synthesis in the alveoli is strictly related to alveolar infection and inflammation; ii) alveolar ceramide (C16) can be 
specifically targeted by nanocarrier delivery of the ceramide synthesis inhibitor Myriocin (Myr); iii) Myr is able to down-
modulate pro-inflammatory lyso-PC, favouring an increase in anti-inflammatory PCs. Conclusions. We concluded that 
Myr modulates alveolar lipids milieu, reducing hyper-inflammation and favouring anti-microbial effective response in 
CF mouse model. 
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Introduction 
Sphingolipids are a large family of molecules which play structural and signalling roles (Aguilera-Romero, 2014). 
Sphingolipid mediators have various involvements in human diseases (Brice 2011, Hammad 2011, Airola 2013, 
Maceyka 2014). Recent findings highlight the role of ceramide among sphingolipids in the pulmonary demise typical of 
chronic obstructive pulmonary disease (COPD) and Cystic Fibrosis (CF) (Grassme 2013, Petrache 2013).  Gulbins and 
coworkers demonstrated that ceramide accumulates in CF airways and that amytriptiline, an inhibitor of the ceramide-
releasing enzyme acid sphingomyelinase, reduces lung inflammation and bacterial infection in mice and in patients 
(Teichgraber 2008, Riethmuller 2009). We recently demonstrated that de novo ceramide synthesis also sustains lung 
inflammation and infection in CF (Caretti 2014) by using a murine CF model and pulmonary Pseudomonas aeruginosa 
infection to measure and pharmacologically target ceramide synthesis. Intratrachea injection of Myriocin (Myr), the 
inhibitor of Serine Palmitoyl Transferase (SPT), reduced inflammation and bacterial infection in CF mice. Although 
significant, the overall ceramide increase upon infection in CF mouse lung was not as striking as expected. We 
suspected that, as previously suggested (Becker 2010, Ulrich 2010), ceramide formation could be compartmentalized, 
and that quantitation on whole lung homogenates could underrate changes that occur in limited areas, such as the 
alveolar compartment. A second major concern raised by our studies considered the disentangling of ambiguities in the 
cause-effect relationship linking ceramide to inflammation and infection. Specifically, it is still unclear whether 
ceramide increases in response to a general inflammatory setting or whether it is a key mediator that drives acute 
response into chronic inflammation and consequent chronic infection. Our aim was to prove that ceramide 
accumulation, inflammation and bacterial colonization not only occur in the same lung region but also are strictly 
dependent on one another. We used different methods (Liquid Chromatography coupled with Mass Spectrometry, LC-
MS, MALDI Imaging, IMS and Confocal Laser Scan Microscopy, CLSM) to analyse the precise topologies of ceramide 
accumulation, P. aeruginosa and the inflammatory infiltrate, and we investigated the effect of ceramide synthesis 
inhibition in alveolar versus bronchial lung regions. We also explored the potential of solid lipid nanocarriers (SLN) 
(Caretti 2014), for in situ delivery of myriocin (Myr) in diseased lungs. SLNs have a solid lipid core, show strong 
interaction with membranes and are a long-lasting drug release system. We wanted to evaluate their pulmonary 
dispersal and to compare the topography of drug action with those of ceramide accumulation, inflammation, and 
consequent infection. Here we describe how we combined multiple in vitro sphingolipid detection methods to cope with 
all of the above issues. Using LC-MS, we precisely quantified single ceramide species and their metabolic derivatives 
(sphingomyelins and cerebrosides) in the whole lung. Using IMS, we were able to map the abundance of precise 
ceramide species onto histological images from lung sections. Furthermore, as this analytical approach allows for the 
simultaneous detection of all molecules in a sample across a broad mass and hydrophobicity range, we correlated 
ceramide changes with overall metabolic changes in other anti-inflammatory lipids, such as phosphatidylcholine (PC) 
(Treede 2007), and pro-inflammatory lipids such as lyso-PC (Yoder 2014), within specific tissue areas. Lastly, through 
immuno-staining and CLSM analyses, we confirmed the topography of ceramide within the lung and contrasted it with 
the location of bacterial infection. We concluded that the integrated use of these three different methodologies is able to 
reveal information that cannot be  deciphered using just one single approach: i) up-regulated ceramide synthesis in the 
alveoli is strictly related to alveolar infection and inflammation; ii) alveolar ceramide (C16) can be specifically targeted 
by SLN delivery of the ceramide synthesis inhibitor Myr; iii) Myr is able to down-modulate the same acyl-chain 
bearing lyso-PC (C16 and C18) with a pro-inflammatory known action (Yoder 2014), favouring the increase in anti-
inflammatory PCs.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3 
 
Methods 
Mice. Twelve weeks old gut-corrected CFTR deficient mice B6.129P2-Cftrtm1UNCTgN(FABPCFTR) (group KO) and 
congenic wild-type (Case Western Reserve University, Cleveland, Ohio, USA) (group WT) male and female mice were 
used. Mice were housed in filtered cages under specific-pathogen conditions and permitted unlimited access to food and 
water. Myriocin (Myr) administration was performed in the treated animals group, 24 hours prior to infection. Once a 
deep stage of anaesthesia with 2,2,2,-tribromoethanol (Avertin, Sigma-Aldrich, US) was reached, Myr loaded SLNs 
were intra-trachea instilled by means of MicroSprayer® Aerosolizer — Model IA1C, attached to “FMJ-250 High 
Pressure Syringe” (Penn-Century Inc., US). Control animals were treated with the corresponding empty SLNs. The total 
volume introduced in lungs was 50 μl, in mice of approximately 30 g each. This volume contained approximately 
1,47 μg of compound/mouse in SLN-saline solution. 24 h after treatment, animals (both KO and WT) were infected 
with 3–10 × 105 CFU of P. aeruginosa strain PAO1 planktonic cells, as previously described (Bragonzi 2010). At 18 h 
post-infection, mice were euthanized and lungs were explanted. Part of the samples were homogenized in 1 ml of PBS 
containing protease inhibitors (Roche Italia, Italy) and homogenates divided in an aliquot for bacterial load counting     
(by serial dilution of homogenate sample in PBS and by plating on TSA) and an aliquot for  lyophilization and lipids 
extraction for LC–MS analysis; part of the samples were embedded  in a modified OCT and prepared for 
immunohistochemistry or IMS (Berry 2011). The other aliquot was serially diluted 1:10 in PBS and plated onto TSA 
plates to determine lung bacterial load. All experiments were performed with a minimum of five animals per group and 
a minimum of two experiments for each kind of investigation method (two experiments for IMS, two experiments for 
LSCM and 4 experiments for LCMS).   
Myriocin loaded-solid lipid nanoparticles (SLN) used for mice treatment. Treatment of mice with Myr was 
achieved by using Myr-loaded SLNs (Nanovector srl, Italy) prepared as previously described. SLN loaded with drug 
were measured for Myr content and a 1 mM Myr-SLN stock solution was prepared. This solution was diluted 1:12 in 
sterile saline and 50 μl (1.47 μg of Myr and 8% SLN) were used for each mouse administration in the airways.                                                                           
LC–MS analysis. Sphingolipid extracts from both mice lungs and treated cells, fortified with internal standards (N-
dodecanoylsphingosine, N-dodecanoylglucosylsphingosine, N-dodecanoylsphingosyl phosphorylcholine, C17-
sphinganine (0.2 nmol each) and C17-sphinganine-1-phosphate (0.1 nmol), were prepared and analyzed as reported as 
reported.                      
Immunostaining and confocal microscopy analysis. Frozen lungs were embedded in OCT (Optimum Cutting 
Temperature-Compound, Leica Instruments, Nussloch, Germany), serial 5-μm thick sections were obtained in a 
cryomicrotome (Leica CM1510) and placed on silanized glass slides. The sections were dried for 3 min at room 
temperature, fixed in 4% buffered formalin for 45 min at 4 °C, rinsed 2 times for 5 min in PBS, post-fixed with 
ethanol–acetic acid 2:1 (v/v) for 5 min at −20 °C, rinsed twice for 5 min in PBS, boiled in 10 mM citrate buffer at pH 
6.0 for 10 min, washed once in distilled water and three times in PBS, and finally used for immunofluorescence. After 
treatment with 10% normal goat serum, the sections were incubated overnight at 4 °C with a mouse anti-ceramide 
monoclonal antibody (Glycobiotech, Germany, diluted 1:100 in 1.5% normal goat serum) and a rabbit polyclonal anti-
T7 directed against .P.aeruginosa (kindly provided by Dr.Pier, 1:50), followed by 1 h incubation with goat anti-mouse 
IgM fluorescein or with goat anti-rabbit IgG texas red-conjugated secondary antibody, respectively (Alexa, diluted 
1:1000 in PBS). Total nuclei were counterstained with the karyophilic dye Hoechst 33258 (300 ng/ml, Sigma) for 3 min 
at room temperature, in the dark, followed by rinsing twice in PBS. Sections on glass slide were then mounted in a 10:1 
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glycerol-PBS medium, pH 8.5, containing 0.1% p-phenylenediamine as anti-quenching agent. Confocal imaging was 
performed on a Leica SP2 confocal microscope (Leica Microsystems), using a 40X (NA: 1.25) oil immersion objective 
and 405, 488 and 633 nm lasers. Images were collected using sequential acquisition process in order to reduce spectral 
crosstalk between channels and stacks collapsed into projection images. Offline handling, segmentation and geometric 
density analysis was developed with LCS software (version 2.6.1; Leica Microsystems).  
Histochemistry. Both lungs from infected KO and WT mice, either pre-treated with SLN-Myr or untreated (SLN-
empty) where fixed in buffered formalin and routinely processed for histopathological evaluation. Briefly, lungs were 
sectioned, and paraffin-included. Twenty serial 3-micron thick sections were cut at a microtome; slides at different 
levels (level 1, 11 and 20) were stained with hematoxylin and eosin to have a comprehensive estimation of the 
distribution of inflammatory infiltrate in all compartments. Slides were observed at a Leika light microscope. Image 
acquisition was performed by the NanoZoomer-XR C12000 series (Hamamatsu Photonics K.K., Tokio, Japan.). The 
site of inflammation (bronchial and bronchiolar compartment- intraparietal and endoluminal- and alveoli) and its 
intensity (low: +, medium: ++ and high: +++) were considered. In each case a median value of flogistic reaction on the 
three compartments was considered.                                                                                                                                                
MALDI-IMS analysis. Lungs from infected CF and WT, either pre-treated or not with SLN-Myr, where explanted 24 
h after infection  fixed, sliced at a thickness of 12 um with a cryostat at 20°C, mounted onto a ITO glass and DHB 
matrix was overlayed by sublimation onto the samples using a sublimation apparatus (ACE Glass) for 20 min at 50 
mTorr pressure at 180 °C. The MALDI-IMS analyses were performed by Ultraflex III time-of-flight mass spectrometer 
(Bruker Daltonics) with a SmartBeam laser operating at 200 Hz in positive linear mode using FlexControl 3.0 and 
FlexImaging 2.1 software packages (Bruker Daltonics). Ions were detected in the 480−900 m/z mass range with a 
sampling rate of 2 GS/s. The lateral resolution for MALDI-IMS was set to 50 μm, and a total of 100 laser shots were 
accumulated per pixel at constant laser power. Two-dimensional ion intensity maps and average spectra were created by 
FlexImaging 2.1 software (Bruker Daltonics). 
In order to identify differentially expressed peaks, tandem mass spectrometry (MS/MS) analysis was performed using 
LIFT-TOF/TOF mode and the product ions characteristic head-group of the lipid was used to classify the lipids of 
interest. 
Statistical Analyses. Fluorescence quantitation and statistical evaluation. On the basis of the histological staining, 
regions of interest (ROIs) were defined in the tissue section using the FlexImaging 2.1 software (Bruker Daltonics), 
ROIs containing the same number of spectra (around 70) were created. Statistical analyses were carried out using the 
ClinProTools 2.2 software (Bruker Daltonics) and, during the preprocessing steps, the extracted mass spectra were 
internally recalibrated, normalized on their total ion and corrected by a baseline subtraction. An average spectrum 
created for each class was used for peak picking and to define integration ranges to be used to obtain the area of each 
peak (m/z species) in each single spectrum. A non paramentric Wilcoxon/ Kruskal−Wallis test was performed, with a 
significance cutoff point of p-value<0.05. A receiver operator characteristic (ROC) analysis was performed to highlight 
peaks discriminating the compared classes (area under curve (AUC) > 0.800). LC-MS and IMS, histochemistry images 
statistical evaluation. Most of the analyses, comparing treated and untreated, were performed by unpaired two tailed T 
student test., p<0,05.  In some cases (reported in figure legend), Anova one way test was performed, p<0,05, followed 
by post-test Bonferroni. 
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Results   
Ceramide levels correlate with P. aeruginosa lung colonies. Wild type (WT) and CFTR knock out (KO) mice were 
infected by intratracheal nebulization of 3x10^5 P. areuginosa CFU.  A group of mice received 50µl containing a 
suspension of Myr loaded SLN (1.47 g/mouse of the compound), 24 hours prior to infection. Mice were sacrificed 24 
hours after infection and lung was explanted for analyses. We measured total ceramide mass and P. aeruginosa lung 
colonies both in WT and KO infected mice, either treated with Myr or untreated. We observed a strong direct 
correlation between lung ceramide content and total pulmonary bacterial colonies (statistical significance p=0.0164), 
showing that ceramide accumulation is closely associated with infection (Figure 1). This occurred both in WT and KO 
mice although, as regards significant differences in absolute values, KO mice were more severely infected and showed 
higher ceramide levels than wild type (Caretti 2014). 
Specific ceramide pools are increased in KO mice and modulated by Myriocin. The analyses of lung homogenate 
revealed similar ceramide species profiles both in WT and KO mice, although a few species are slightly but 
reproducibly higher in KO (mean value of total ceramide picomoles per milligram of protein in WT mice 839.3± 61 
versus KO mice 1058.2 ± 49, p= 0.038). Treatment with SLN-Myr reduced almost all ceramide species, both in WT and 
KO mice (Figure 2A). Specifically, higher significance in Myr induced reduction was observed in the most 
representative ceramide species (Figure 2A), (as C16 ceramide, mean ± SD: KO untreated 178 ± 16,9 versus treated 
97.9 ±10.2; saturated C24-ceramide, KO treated: 217 ± 49.6 versus untreated 509.8 ± 4 9.2; mono-unsaturated C24:1-
ceramide, KO treated 97.9 ± 10.2 versus untreated 178.6 ± 16.9). Although a minor species, C18-ceramide was 
significantly reduced by half (mean ± SD: KO treated 12.6  ± 1.5 versus untreated 23.8 ± 3.6). These observations 
suggest that KO mouse lung, upon infection, undergoes an increased synthesis of ceramide, mainly affecting C16 and 
C24 saturated/mono-unsaturated ceramides, compared to WT mouse lung. This  is also supported by the previously 
reported increase of serine palmitoyl transferase expression in the same KO versus WT infected mice (Caretti 2014). No 
significant variability was observed in the sphingomyelins pools (Figure 2B), whereas mono-glycosylated ceramides 
were affected by Myr treatment, with the C16 and C18 acyl-chain species being significantly reduced in KO treated 
versus untreated lungs (Figure 2C).  When considering the percentage change in ceramides in the KO and WT mice, it 
is interesting to note that the Myr-induced reduction in the percentage of C16, C18 and C24 ceramides is significantly 
higher in KO than in WT mice (Figure 2D), indicating that de novo ceramide synthesis is enhanced and drug treatment 
is effective in CF murine model lung.  
Inflammatory lyso-PC is reduced by Myriocin in infected mice. PC is a known anti-inflammatory lipid and oral 
phosphatidylcholine alleviates inflammatory activity caused by ulcerative colitis (Stremmel 2005). Lyso-PC is obtained 
through the action of cPLA2 on PC and exerts pro-inflammatory actions. Choline is shared among sphingolipids and 
glycerophospholipids, being incorporated into SM and PC, and ceramide is able to activate cPLA2 (Sato et al. 2009, 
Kitatani et al. 2000, Huwiler et al 2001). We observed a slight but consistent increase in PC, with a particularly high 
mass in cells and tissue, and a significant drop in lyso-PC (mean value of lyso-PC picomoles per milligram of protein 
±SD: value 5167±99 vs 4393±200) in infected and Myriocin-treated KO mice versus infected and untreated mice 
(Figure 3A and B). Since PC mass is particularly high in tissue and cells, a slight increase must be taken into account. 
PC can be metabolized in different by-products, so LysoPC basal levels are normally much lower and its increase along 
with an increase in ceramide synthesis indicates that, in KO mice, it is able to modulate glycerophospholipid pools and 
promote the formation of pro-inflammatory lyso-PC.   
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Localization of ceramide and P. aeruginosa within the lungs. In order to understand the meaning of ceramide 
increase, we investigated the topology of its accumulation within the lung and co-related it to P. aeruginosa localization 
using confocal laser scanning microscopy. 24 hours after infection or Myr-treatment and infection, the lungs of KO and 
WT mice were explanted and stained with anti-ceramide antibodies and with anti-P. aeruginosa antibodies. Myr 
treatment succeeded in reducing both ceramide and P. aeruginosa PAO1 strain in the alveolar and bronchial regions 
(Figure 4A and 4B).  The quantitation of immunofluorescence, deriving from DAPI positive cells only, provided us 
with confirmation of LC-MS data and allowed us to discriminate between alveolar and bronchial ceramides. We 
measured an increased ceramide signal in infected KO versus WT lungs and a slight but significant increase in P. 
aeruginosa infection in KO lungs (Figure 4C), in agreement with the LC-MS quantitation of ceramides and the CFU 
count of Figure 1We also found a higher accumulation of ceramide in the alveolar areas (Figure 4 A, infected only WT 
panel A and KO infected only panel G), an overlap of P. aeruginosa in the alveolar regions with ceramides (Figure 4A, 
infected only WT panel C and KO infected only panel I), and a reduction in P. aeruginosa (Figure 4A WT infected and 
treated, panel E, KO infected and treated, panel K) and a dramatic reduction in ceramide in these areas (Figure 4A WT 
infected and treated, panel D, KO infected and treated, panel J) following Myr treatment.  
Ceramide and immune infiltrate located in the alveolar areas. 
In our previous publication, we demonstrated that Myr is able to reduce the transcription of inflammatory mediators by 
evaluating the whole lung homogenate of KO and WT mice (Caretti 2014), although we were unable to obtain 
significant differences in the inflammatory cells present in BAL of treated and untreated mice. In order to clarify the 
role of Myr in the acute immune response, we used light microscopy to evaluate the presence of infiltrate in infected 
KO and WT mice, either treated with Myr or untreated. We noticed a basal difference between infected KO and WT 
mice, with the former exhibiting a higher and more widespread infiltrate, especially in the lower airways (bronchioli 
and alveoli, Figure 5 a, b, c, g, h, i).  We observed a dramatic reduction of inflammatory cells in Myr treated lungs 
(Figure 5 WT mice d, e, f and  KO mice l, m, n), which was particularly evident in the KO alveolar areas (n). In treated 
mice, flogosis showed a “patchy” pattern, with almost healthy areas near unhealthy zones; where groupss of neutrophils 
and, to a lesser extent, macrophages were commonly detected. In untreated mice, the same inflammatory reaction 
involved all the compartments studied equally. The results are summarized in table 1. These observations confirm that 
localized control of sphingolipid metabolism, obtained through alveolar Myr delivery, is highly effective in lung 
infection and inflammation. We concluded that SLN drug delivery is highly suitable for alveolar targeting.  
Quantification and topology in vivo of single ceramide species. 
In order to confirm the localization of ceramide and to obtain its quantitative fluctuation within tissue, we performed a 
MALDI Imaging analysis. Lungs from infected CF and WT mice, some of which pre-treated with SLN-Myr, were 
explanted 24 h after infection. They were then fixed, sliced and embedded into matrix for MALDI-TOF analysis. 
Utilizing hematoxylin and eosin-stained images, ROIs of lung sections were defined in each MALDI-IMS experiment 
and peak areas within the 480-900 m/z range were then submitted to statistical analysis. Slices were also scanned and 
stained for histochemistry, and the images were overlapped. As far as ceramide species were concerned, a 538.20 m/z 
peak, corresponding to C16-ceramide, was detected in all samples, and the peak level was reduced using SLN-Myr 
treatment in both WT and KO mice, in accordance with UPLC-TOF data (Fig. 6A). Moreover, the extracted-ion 
MALDI image of the 538.20 m/z peak, indicates a relatively even intensity within the lung parenchyma (Fig 6B), while 
SLN-Myr treatment reduces C16 ceramide in the alveolar region more than in the bronchial region, both in WT and KO 
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mice (Figure 6 panel A versus C). To better characterize sphingolipid differences related to treatment in WT and KO 
mice and find other species capable of discriminating these groups, a statistical analysis of spectra obtained through 
MALDI-IMS experiments was performed using ClinProTools software. In particular, a ROC analysis was performed to 
highlight discriminating peaks (AUC > 0.800).  By comparing WT Myr-untreated versus treated, we found 30 
differentially expressed peaks (12 increased and 18 decreased after pharmacological treatment) with p<0.5 and CV<20 
% (table 1), nine of which were identified by MALDI-LIFT-MS/MS analysis directly on tissue slices (Supplementary 
figures 1-10). The whole analysed slice is reported in figure 7A. The positive-ion collision-induced dissociation (CID) 
analysis of m/z 496.42 and 524.52 peaks identified C16 and C18 lyso-PC, respectively (Figure 7B and C). As found for 
C16-Cer, these ions had lower intensities in treated samples than in those that were not treated and were evenly 
distributed in the lung slice (Fig 7B and C). On the other hand, peaks at m/z 732.78, 754.72, 780.67, 782.68, 804.58 and 
806.59, corresponding to 32:1-PC (M+1), 32:1-PC (M+ Na), 34:2-PC (M+ Na), 34:1-PC (M+ Na), 36:4-PC (M+ Na) 
and 38:6-PC (M+1), respectively, were higher in treated samples. In addition, 32:1-PC (M+1), 32:1-PC (M+ Na) and 
34:1-PC (M + Na) showed a distribution very similar to C16-Cer and lysoPC species (Fig 7D, E and G), whereas the 
signal corresponding to 34:2-PC (M + Na) was evenly distributed across the lung slice with a slight increment in the 
bronchus region (Fig. 7F). By contrast, MALDI analysis of 36:4-PC (M + Na) and 38:6-PC (M+1) indicated that these 
phospholipid molecular ions were highly abundant along the bronchus and were also present in the alveolar region (Fig. 
7H and I). Regarding the comparison between untreated versus treated KO mice, 14 differentially expressed peaks (7 
increased and 7 decreased after pharmacological treatment) with p<0.5 and CV<20 % were detected (table 2), and five 
of them were identified by MALDI-LIFT-MSMS analysis (Supplementary figure 1). In particular, peaks at m/z 732.78, 
754.72, 760.78, 770.69 and 780.78, corresponding to 32:1-PC (M+1), 32:1-PC (M + Na), 34:1-PC (M + 1), 32:1PC (M 
+ K) and 34:2-PC (M + Na), respectively, were augmented in treated samples. Identified phosphatidylcholines showed 
even distribution along the tissue slice with the exception of 34:2-PC, which was only slightly expressed in the 
bronchus (Fig.8). Overall, data obtained using IMS demonstrate that: i) C16-ceramide is  more abundant in alveolar 
areas and ii) C16-ceramide and lyso-PCs, the latter being known pro-inflammatory mediators, are reduced with Myr 
treatment, favouring an increase in PC (see hypothesis scheme, Figure 9).    
 
Discussion 
The study of sphingolipid mediators is quite challenging due to the large number of bioactive molecules metabolically 
converting one into another, their different signalling in relation to subcellular distribution or extracellular release, their 
subtle switches from homeostatic concentration to accumulation and related “alarm-stress” signals and, last but not 
least, their diverse level of hydrophobicity, requiring appropriate extraction from samples. This document aims to 
embrace different analytical techniques and integrate all the data obtained, in order to achieve conclusions that cannot 
be fully deduced from a single analysis.  After decades of sphingolipid evaluation using labelled precursors, in vitro or 
in vivo, the arrival of LC-MS analysis for lipidomic studies allows accurate quantitation and, moreover, the distinction 
among all different species. The evaluation of single species fluctuations has opened up the possibility to define actions 
and metabolic routes for previously under-estimated molecules such as C18-  versus C16-ceramide (Karahatay 2007), 
dihydroceramides versus ceramides (Fabrias 2012), as well as sphingosine-1-phosphate versus sphingosines (Takabe 
2008) and ceramide-1-phosphate versus ceramide (Gomez-Munoz 2006).  Despite representing a step forward, this 
method cannot consider the scenario of sphingolipid modulation, which is orchestrated by environmental stimuli within 
a single body. Therefore, sphingolipid modulation can occur as a result of a given stress but not elsewhere, such as in 
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the brain at the outset of Alzheimer’s or Parkinson’s (Fabelo 2011, Fiedorowicz 2014, Panchal 2014), or in lung 
infection and inflammation (Ulrich 2010). Research requires the identification of the location of sphingolipid action 
both for the evaluation of their role and in order to approach pharmacological targeting. Immunocytochemical studies 
have been applied for the location of ceramides within tissue. In 1992, an interesting article by Hannun’s group was 
published in JLR, assessing and questioning the specificity and the reliability of different ceramide antibodies (Cowart 
2002). Being mostly membrane embedded, it is quite difficult to detect the specific binding of ceramide antibody, 
although several authors reported successful use of this tool.  IMS, an innovative recent application of MALDI imaging 
to MS, can trace lipid variation directly on tissue slides without extraction, thus maintaining all the information related 
to their location. Although hard to consider as a quantitative analysis, IMS is a highly promising tool for research on 
sphingolipids roles in vivo. One of our main unanswered questions was “how is ceramide accumulation related to lung 
infection?”. On one hand, ceramide deriving from increased plasma membrane sphingomyelinases activity, previously 
demonstrated by other authors (Riethmuller 2009), can be a consequence of the engagement of pattern-recognition or 
inflammatory mediator receptors, within the context of a self-resolving inflammatory response triggered by acute 
bacterial infection. On the other, the increase of the rate-limiting enzyme of de novo sphingolipid synthesis, recently 
reported by us and by others in lung inflammation (Petrache 2013, Caretti 2014), is probably due to a metabolic switch 
of the airways’ epithelia, which is partially responsible for the chronic inflammation that characterizes CF-diseased lung 
and encourages infection rather than opposing it. In our CF mice model, we observed an anti-inflammatory effect of 
Myr associated to a decrease in bacteria lung colonization. We demonstrated that Myr was more effective in KO than 
WT mice (Figure 2D). We concluded that ceramide increase is particularly enhanced in KO mice, via its de novo 
synthesis, and Myr is specifically effective in counteracting sphingolipid-altered metabolism in CF.  In support of this 
idea, thanks to precise quantitation offered by LC-MS and with the broad insight offered by IMS, we found that other 
pro-inflammatory lipids are up-regulated at the same time as ceramide, suggesting a comprehensive lipid dysmetabolic 
reaction to infection. It is important to note that the pharmacological inhibition of ceramide synthesis is able to regulate 
other inflammatory lipids, by reducing known inflammatory lyso-PC production (Yoder 2014) and increasing the 
accumulation of anti-inflammatory PC (Treede 2007). Lyso-PC derives from phospolipases activity and it was 
previously reported that ceramide is able to activate cytosolic PLA2 (Sato et al. (1999), Kitatani et al. (2000), Huwiler 
et al. 2001), possibly creating a metabolic loop between the two inflammatory molecules.  It is interesting to note that 
species containing saturated C16 (and C18) acyl chains, previously reported to have specific inflammatory activity 
(Yoder 2014), are significantly reduced both in ceramides and lyso-PC families, suggesting that Myr treatment may 
control palmitate availability for other metabolic reactions, such as the formation of  anti-inflammatory PC, thanks to 
the down-modulation of  stress-induced ceramide synthesis,.  These data highlight a central role for ceramide 
metabolism in the metabolism of inflammatory lipids and suggest that the rate of de novo sphingolipid synthesis is 
carefully balanced and plays a sentinel role in the response to stress and in the switch to a pathological state.  This is an 
important concept that requires exploration in other chronic inflammatory settings with the aim of being considered as a 
therapeutic target.  Moreover, our data confirm the idea that bacterial infection from the upper airways reaches the inner 
lungs and that there is a significant burden of alveolar epithelia favoured by local ceramide accumulation, and 
consequent recruitment of inflammatory cells. The demonstrated phenotype switch in the infectious population and the 
acquisition of resistance mechanisms (Bragonzi 2009) can be associated with bacterial flow from the upper to lower 
airways and, lastly, the alveoli (McAdam 2011). It is mandatory to approach drug delivery methods that ensure the 
targeting of the alveolar region. Myr treatment evidenced an overall reduced inflammation with pro-resolving patchy 
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granulocyte aggregates and no inflammation-related extensive damage of the alveolar structure. Our Solid Lipid 
Nanoparticles demonstrated a marked ability to reach the alveolar compartment and to efficaciously release the drug. 
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Legends  
Table 1. A sum up of the histochemistry analyses result is provided in the the table: IP,intraparietal; EL, endoluminal; 
P, patchy; D, diffuse; :+low; ++ medium; +++ high inflammatory infiltrate. 
.Table 2. Differentially expressed peaks (p < 0.05) obtained by comparison between untreated and SLN-Myr treated 
wild-type mice. For each peak p-value obtained adopting a non-parametric test (Wilcoxon test), class average areas, 
CV, ROC value and assignment are indicated. 
Table 3. Differentially expressed peaks (p < 0.05) obtained by comparison between untreated and SLN-Myr treated 
knock-out mice. For each peak p-value obtained adopting a non-parametric test (Wilcoxon test), class average areas, 
CV, ROC value and assignment are indicated 
Figure 1. Correlation of total ceramide levels with lung infection. Total ceramides were measured by LC-MS and CFU 
counts were collected from lung homogenates. Data were obtained from KO and WT mice either untreated (SLN-
empty) or treated with SLN-Myr. Three separate experiments were conducted. Linear regression afforded a P values of 
0.0164 
Figure 2. LC-MS quantification of different acyl species ceramides (A), sphingomyelins (B) and mono-glycosylated 
ceramides (glucose or galactose) (C), in Myriocin treated (SLN-Myr) versus untreated (SLN-empty) KO and WT total 
lung homogenates. Sphingolipids picomoles are normalized onto proteins milligrams per sample. Unpaired student t test 
two tails was performed, between Myriocin treated versus untreated. *= p<0.05,  **=p<0.01. Panel (D) shows the 
percentage of the three most representative ceramides (bearing C16:0 or C18:0 or C24:0 fatty acid acyl chain). 
Untreated  KO or WT were considered as 100% of each ceramide specie (gray bars), and the percentages of ceramides 
were calculated in  Myriocin treated  lung homogenates. Data shows a significantly higher reduction of ceramides in 
KO-treated lung homogenate than in WT. Anova test was performed among all groups (p<0,0001), followed by 
Bonferroni test in KO versus WT single chains ceramides ***= p<0,001 
Figure 3. LC-MS quantification of phosphatidylcholine (PC) (A) and lyso-phosphatidylcholine (lyso-PC) (B) in total 
lung homogenates from Myriocin treated (SLN-Myr) versus untreated (SLN-empty) infected KO and infected WT 
mice. Lipids picomoles are normalized onto proteins milligrams per sample. Unpaired student t test two tails was 
performed, between Myriocin treated versus untreated; *, p<0,05.  
Figure 4. Ceramide and PAO1 localization in the lung. Confocal laser scan images, most representative of alveolar (A) 
and bronchial (B) areas .Left vertical lane: anti-ceramide fluorescence (green); middle vertical lane anti-P.aeruginosa 
fluorescence(red); right vertical lane overlapping of the two staining. a,b,c) WT mice untreated (SLN-empty); d,e,f) WT 
mice treated with SLN-Myr; g,h,i) KO mice untreated (SLN-empty); l,m,n) KO mice treated with SLN-Myr. Images are 
stack average projections, bar = 50 m.  C) Total lung Ceramide content and PAO1 infection (immunofluorescence 
quantitation). Statistical evaluation was performed by Unpaired t-test: *, p<0,05, ceramide in KO treated versus KO 
untreated; #, p<0,05, PAO1 in KO untreated versus WT untreated. D) Ceramide content (immunofluorescence 
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quantitation) in alveolus versus broncus, in infected or infected and myriocin treated KO mice. Statistical evaluation 
was performed by Unpaired t-test: *, p<0,05, ceramide in KO treated versus KO untreated. 
Figure 5. Lung histology. a, b, c: WT mice infected/ untreated; d, e, f: WT mice infected/treated with Myriocin. g, h, i :  
KO mice infected/untreated; l, m, n: KO mice infected/treated with Myriocin. WT empty. a): bronchial lumina and 
walls are free from inflammatory elements. b): moderate inflammatory cells are detected both in the lumen and in the 
walls of bronchiole. c): diffuse moderate inflammatory elements invading alveoli, even in sub-pleural areas. d): no 
inflammatory infiltrate is detected in or around large bronchi. e): sporadic inflammatory cells are observed in the 
bronchiolar walls and only rarely, in the bronchiolar lumen. f): Very weak inflammatory infiltrate in the alveolar 
compartment;     g & h) very dense inflammatory infiltrate (black arrows) is easily visible in the lumen of large (g) and 
small (h) airways, as well as in the surrounding parenchima.i): heavy flogistic infiltrate diffusely infiltrate lung alveoli; 
l): inflammatory infiltrate in the walls of a large broncus and in peri-bronchial tissues (arrow); no flogistic elements are 
observed in the lumen (L). m): inflammatory elements are detected in the bronchiolar walls and at a lesser extent, in the 
lumen (L). A weak to moderate infiltrate is also observed in the alveolar compartment in a pathway pattern. n): Weak 
patchy inflammatory alveolar infiltrate reaches the sub-pleural areas. 
Figure 6. Ceramide distribution in the lung. MALDI Imaging analysis of 538.2 m/z peak, corresponding to C16:0 
ceramide. (A) Box plots indicating the expression of 538,2 m/z peak in the lung tissue of  wild type (WT) and CF (KO) 
mice, either untreated (SLN-empty) or myriocin treated (SLN-Myr)  (B) Distribution of 538.2 m/z peak (blue color) in 
lung tissue of WT and KO mice with and without pharmacological treatment. (C) Box plots indicating the expression of 
538,2 m/z peak in wild type and  knock-out mice with and without myriocin treatment only in the bronchial area. For 
bronchi and alveoli distinction, hematoxylin-eosin staining was obtained on the same slices and MALDI image was 
overlapped to histochemistry image.  
Figure 7. MALDI Imaging analysis of differentially expressed and identified peaks in untreated versus SLN-Myr 
treated wild-type mice lung. Distribution, box plots and ROC curve of (B) lysoPC (16:0) (C) lysoPC (18:0) (D) PC 
(32:1), (E) PC (32:1) + Na, (F) PC (34:2) + Na, (G) PC (34:1) + Na, (H) PC (36:4) + Na and (I) PC (38:6) are shown. 
Figure 8. MALDI Imaging analysis of differentially expressed and identified peaks in untreated versus SLN-Myr 
treated KO mice lung. Distribution, box plots and ROC curve of (B) PC (32:1), (C) PC (32:1) + Na, (D) PC (34:1), (E) 
PC (32:1) + K, and (F) PC (34:2) + Na are shown. 
Figure 9. Scheme: hypothesis of Myr regulating inflammatory lipids. Red, inflammatory mediators; green, anti-
inflammatory mediators; gray, data derived from literature (not presented in the manuscript). 
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  Infiltrate evaluation  Bronchus Brochiolus Alveolus 
 IP EL IP EL IP EL 
WT SLN-empty - - ++D ++D +D +D 
WT SLN-Myr - -    +P - - - 
KO SLN-empty +D +D +++D +++D ++D ++D 
KO SLN-Myr +P - ++P +P +P P 
Table1
Peak Mass 
Wilcoxon 
p-value 
WT average 
area value 
CV(%) 
WT 
WT+Myr average 
area value 
CV(%)  
WT + Myr 
ROC 
value 
Assignment 
754.72 0.00569 6.95 6.28 8.76 3.59 0.925 PC (32:1) + Na 
772.66 0.00569 5.89 8.82 4.39 5.59 0.940 PC (32:0) + K 
780.67 0.00569 4.11 5.70 5.51 4.41 0.986 PC (34:2) + Na 
732.78 0.00569 3.96 12.58 5.26 5.68 0.854 PC (32:1) 
782.68 0.00569 6.29 4.65 7.45 6.73 0.902 PC (34:1) + Na 
741.75 0.00569 2.48 8.67 1.37 13.18 0.985  
675.26 0.00569 2.29 16.85 1.37 12.76 0.914  
744.71 0.00569 2.76 6.04 1.89 7.56 0.925  
742.76 0.00569 2.82 8.00 2.02 10.80 0.910  
828.49 0.00569 1.63 9.20 2.37 6.67 0.953  
804.58 0.00569 1.67 8.30 2.36 6.99 0.943 PC (36:4) + Na 
806.59 0.00569 1.97 7.16 2.65 11.41 0.896 PC (38:6) 
691.21 0.00569 0.86 9.65 0.43 8.51 0.993  
752.70 0.00569 0.62 8.36 0.99 6.54 0.963  
851.47 0.00569 1.14 17.55 0.79 11.72 0.838  
824.52 0.00569 1.11 8.18 0.77 8.90 0.941  
534.48 0.00569 0.61 11.74 0.28 14.61 0.984  
826.52 0.00569 0.86 7.88 0.60 8.54 0.944  
562.57 0.00569 0.54 13.12 0.30 13.23 0.932  
802.58 0.00569 0.81 7.89 1.04 4.16 0.895  
822.51 0.00569 0.78 6.26 0.61 7.87 0.879  
856.40 0.00569 0.56 6.91 0.71 9.47 0.843  
635.45 0.00569 0.23 19.80 0.11 12.98 0.969  
538.17 0.00569 0.26 19.45 0.16 8.83 0.818 Cer C16 
700.76 0.00569 0.34 4.85 0.41 7.98 0.885  
666.78 0.00569 0.3 6.76 0.24 6.83 0.835  
524.52 0.0187 0.72 19.01 0.45 13.43 0.857 LysoPC (18:0) 
496.42 0.0292 1.05 17.98 0.72 14.89 0.816 LysoPC (16:0) 
848.41 0.0292 0.52 7.78 0.43 9.95 0.803  
672.72 0.0466 0.41 11.00 0.53 16.54 0.808   
 
Table2
 Peak Mass 
Wilcoxon 
p-value 
KO average 
area value 
CV(%) 
KO 
KO + Myr 
average area 
value 
CV(%)  
KO + Myr 
ROC 
value 
Assignment 
754.75 0.00222 8.43 10.38 10.88 3.52 0.853 PC (32:1) + Na 
732.82 0.00222 5.01 8.76 7.12 4.70 0.866 PC (32:1) 
567.27 0.00222 2.06 20.53 0.72 17.41 0.995  
770.69 0.00222 4.33 8.59 5.50 8.49 0.842 PC (32:1) + K 
760.78 0.00222 4.50 7.91 5.44 5.70 0.825 PC (34:1) 
583.27 0.00222 1.03 16.52 0.47 14.20 0.976  
588.28 0.00222 0.32 17.25 0.14 12.35 0.979  
572.28 0.00222 0.31 16.47 0.17 8.84 0.961  
538.20 0.00222 0.24 13.43 0.13 15.90 0.908 Cer C16 
577.82 0.00222 0.16 7.94 0.26 10.38 0.919  
627.89 0.00222 0.16 12.37 0.25 11.47 0.896  
511.17 0.00222 0.18 15.03 0.11 16.95 0.881  
780.70 0.0114 5.63 0.36 6.41 0.34 0.807 PC (34:2) + Na 
650.79 0.0114 0.29 19.73 0.19 15.14 0.808   
Table3
